Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Axicabtagene ciloleucel & Large B-cell lymphoma (LBCL) / Diffuse Large B-Cell Lymphoma (DLBCL)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

FDA status:

In the context of Axicabtagene ciloleucel & Diffuse Large B-Cell Lymphoma (DLBCL), the FDA first approved axicabtagene ciloleucel in October 2017 for adults with relapsed/refractory large B‑cell lymphoma after ≥2 prior systemic regimens, including Large B-cell lymphoma (LBCL) / Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified, high‑grade B‑cell lymphoma, primary mediastinal large B‑cell lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL) arising from follicular lymphoma. Usually, a specific lymphodepleting regimen (fludarabine + cyclophosphamide) as part of the indicated treatment is embed…

References (Sources)

Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas
Reagan & Friedberg 2021 Future Oncology 17: 1269–1283
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma
Thiruvengadam et al. 2022 Blood 140(19): 2024-2036
EMA Review of Axicabtagene Ciloleucel (Yescarta) for the Treatment of Diffuse Large B-Cell Lymphoma
Papadouli et al. 2020
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial
Locke et al. 2019 Lancet Oncol 20: 31-42
Overview of approved CAR-T products and utility in clinical practice
Bhaskar et al. 2024 Clin Hematol Int 6(4): 93-99
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Nastoupil et al. 2020 JCO 38: 3119–3128
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
Chow et al. 2018 Blood 132(8): 777-781

AI Chat

7/1/2026

Chat with our artificial intelligence: